These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 34675044)

  • 1. Mortality trends in pulmonary arterial hypertension in Canada: a temporal analysis of survival per ESC/ERS guideline era.
    Zelt JGE; Sugarman J; Weatherald J; Partridge ACR; Liang JC; Swiston J; Brunner N; Chandy G; Stewart DJ; Contreras-Dominguez V; Thakrar M; Helmersen D; Varughese R; Hirani N; Umar F; Dunne R; Doyle-Cox C; Foxall J; Mielniczuk L
    Eur Respir J; 2022 Jun; 59(6):. PubMed ID: 34675044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening for pulmonary arterial hypertension in patients with systemic sclerosis in the era of new pulmonary arterial hypertension definitions.
    Erdogan M; Kilickiran Avci B; Ebren C; Ersoy Y; Ongen Z; Ongen G; Hamuryudan V; Hatemi G
    Clin Exp Rheumatol; 2024 Aug; 42(8):1590-1597. PubMed ID: 38489342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mixed Venous Oxygen Saturation Is a Better Prognosticator Than Cardiac Index in Pulmonary Arterial Hypertension.
    Khirfan G; Almoushref A; Naal T; Abuhalimeh B; Dweik RA; Heresi GA; Tonelli AR
    Chest; 2020 Dec; 158(6):2546-2555. PubMed ID: 32629034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective Database Analysis of Treatment Patterns Among Patients with Pulmonary Arterial Hypertension.
    Studer S; Hull M; Pruett J; Elliott C; Tsang Y; Drake W
    Pulm Ther; 2020 Jun; 6(1):79-92. PubMed ID: 32048240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Management of Patients with Pulmonary Arterial Hypertension: Insights from EXPOSURE.
    Muller A; Escribano-Subias P; Fernandes CC; Fontana M; Lange TJ; Söderberg S; Gaine S
    Adv Ther; 2024 Mar; 41(3):1103-1119. PubMed ID: 38216826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simplified risk stratification for pulmonary arterial hypertension associated with connective tissue disease.
    Li X; Sun X; Huang Y; Wang Y; Yang X; Wang J; Zhang N; Gu L; Zhang M; Wang Q
    Clin Rheumatol; 2019 Dec; 38(12):3619-3626. PubMed ID: 31385084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-center prognostic validation of the risk assessment of the 2015 ESC/ERS guidelines in patients with pulmonary arterial hypertension in Japan.
    Imai R; Adachi S; Yoshida M; Shimokata S; Nakano Y; Okumura N; Murohara T; Kondo T
    Can J Physiol Pharmacol; 2020 Sep; 98(9):653-658. PubMed ID: 32924564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. European Society of Cardiology quality indicators for the care and outcomes of adults with pulmonary arterial hypertension. Developed in collaboration with the Heart Failure Association of the European Society of Cardiology.
    Aktaa S; Gale CP; Brida M; Giannakoulas G; Kovacs G; Adir Y; Benza RL; Böhm M; Coats A; D'Alto M; Escribano-Subias P; Ferrari P; Galiè N; Gibbs JSR; Gin-Sing W; Hoeper MM; Humbert M; Lang IM; Maron BA; Meszaros G; Vonk Noordegraaf A; Price LC; Pepke-Zaba J; Rådegran G; Reis A; Sitbon O; Torbicki A; Ulrich S; Rosenkranz S; Delcroix M
    Eur J Heart Fail; 2023 Apr; 25(4):469-477. PubMed ID: 36924171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the European Society of Cardiology/European Respiratory Society derived three- and four-strata risk stratification models in pulmonary arterial hypertension: introducing an internet-based risk stratification calculator.
    Ahmed A; Ahmed S; Kempe D; Rådegran G
    Eur Heart J Open; 2023 Mar; 3(2):oead012. PubMed ID: 36959867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of patients with decreased arterial oxyhaemoglobin saturation on pulmonary arterial hypertension drugs.
    Valentin S; Maurac A; Sitbon O; Beurnier A; Gomez E; Guillaumot A; Textoris L; Fay R; Savale L; Jaïs X; Montani D; Picard F; Mornex JF; Prevot G; Chabot F; Humbert M; Chaouat A
    Eur Respir J; 2021 Oct; 58(5):. PubMed ID: 33875491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term impact of add-on sequential triple combination therapy in pulmonary arterial hypertension: real world experience.
    Deshwal H; Weinstein T; Salyer R; Thompson J; Cefali F; Fenton R; Bondarsky E; Sulica R
    Ther Adv Respir Dis; 2023; 17():17534666231199693. PubMed ID: 37795626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies.
    Benza RL; Gomberg-Maitland M; Elliott CG; Farber HW; Foreman AJ; Frost AE; McGoon MD; Pasta DJ; Selej M; Burger CD; Frantz RP
    Chest; 2019 Aug; 156(2):323-337. PubMed ID: 30772387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes and prognostic factors of decompensated pulmonary hypertension in the intensive care unit.
    Garcia MVF; Souza R; Costa ELV; Fernandes CJCS; Jardim CVP; Caruso P
    Respir Med; 2021 Dec; 190():106685. PubMed ID: 34823189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Refined risk stratification, current treatment, and new therapeutic approaches in pulmonary arterial hypertension.
    Lange TJ
    Herz; 2023 Aug; 48(4):259-265. PubMed ID: 37085727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry.
    Hoeper MM; Pausch C; Grünig E; Staehler G; Huscher D; Pittrow D; Olsson KM; Vizza CD; Gall H; Distler O; Opitz C; Gibbs JSR; Delcroix M; Ghofrani HA; Rosenkranz S; Park DH; Ewert R; Kaemmerer H; Lange TJ; Kabitz HJ; Skowasch D; Skride A; Claussen M; Behr J; Milger K; Halank M; Wilkens H; Seyfarth HJ; Held M; Dumitrescu D; Tsangaris I; Vonk-Noordegraaf A; Ulrich S; Klose H
    Eur Respir J; 2022 Jun; 59(6):. PubMed ID: 34675047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes and risk assessment in pulmonary veno-occlusive disease.
    Boucly A; Solinas S; Beurnier A; Jaïs X; Keddache S; Eyries M; Seferian A; Jevnikar M; Roche A; Bulifon S; Bourdin A; Chaouat A; Cottin V; Bertoletti L; Savale L; Humbert M; Sitbon O; Montani D
    ERJ Open Res; 2024 Jan; 10(1):. PubMed ID: 38226059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incorporation of renal function in mortality risk assessment for pulmonary arterial hypertension.
    Zelt JGE; Hossain A; Sun LY; Mehta S; Chandy G; Davies RA; Contreras-Dominguez V; Dunne R; Doyle-Cox C; Wells G; Stewart DJ; Mielniczuk LM
    J Heart Lung Transplant; 2020 Jul; 39(7):675-685. PubMed ID: 32336606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic role of haemodynamics at follow-up in patients with pulmonary arterial hypertension: a challenge to current European Society of Cardiology/European Respiratory Society risk tools.
    Dardi F; Guarino D; Ballerini A; Bertozzi R; Donato F; Cennerazzo F; Salvi M; Nardi E; Magnani I; Manes A; Galiè N; Palazzini M
    ERJ Open Res; 2024 Jul; 10(4):. PubMed ID: 39104950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dart to the target: an alternative bull's eye parametric display for European Society of Cardiology / European Respiratory Society goal-orientated risk reduction strategy in pulmonary arterial hypertension.
    Kaymaz C; Akbal OY; Hakgor A; Tokgoz HC; Tanyeri S
    Pulm Circ; 2018; 8(3):2045894018780522. PubMed ID: 29767575
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.